Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease

S Verma, M Al‐Omran, LA Leiter… - Diabetes, Obesity …, 2022 - Wiley Online Library
Aim To evaluate the cardiovascular (CV) efficacy of liraglutide and semaglutide in patients
with type 2 diabetes (T2D) and peripheral artery disease (PAD). Materials and Methods …
被引用次数：32 相关文章

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.

S Verma, M Al‐Omran, LA Leiter… - Diabetes, Obesity & …, 2022 - search.ebscohost.com
Aim: To evaluate the cardiovascular (CV) efficacy of liraglutide and semaglutide in patients
with type 2 diabetes (T2D) and peripheral artery disease (PAD). Materials and Methods …

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease

S Verma, M Al-Omran, LA Leiter… - Diabetes, obesity & …, 2022 - pubmed.ncbi.nlm.nih.gov
Aim To evaluate the cardiovascular (CV) efficacy of liraglutide and semaglutide in patients
with type 2 diabetes (T2D) and peripheral artery disease (PAD). Materials and methods …
[HTML] nih.gov

[HTML][HTML] Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease

S Verma, M Al‐Omran, LA Leiter… - Diabetes, Obesity & …, 2022 - ncbi.nlm.nih.gov
Aim To evaluate the cardiovascular (CV) efficacy of liraglutide and semaglutide in patients
with type 2 diabetes (T2D) and peripheral artery disease (PAD). Materials and Methods …

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.

S Verma, M Al-Omran, LA Leiter, CD Mazer… - Diabetes, Obesity & …, 2022 - europepmc.org
Aim To evaluate the cardiovascular (CV) efficacy of liraglutide and semaglutide in patients
with type 2 diabetes (T2D) and peripheral artery disease (PAD). Materials and methods …
[PDF] researchgate.net

[PDF][PDF] Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease

S Verma, M Al-Omran, LA Leiter, CD Mazer… - 2022 - researchgate.net
Aim: To evaluate the cardiovascular (CV) efficacy of liraglutide and semaglutide in patients
with type 2 diabetes (T2D) and peripheral artery disease (PAD). Materials and Methods …